PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS - Barnes, E; Folgori, A; Capone, S; Aston, S; Meyer, J; Gantlett, K; Smith, K; Huddart, R; Brown, A; Kurioka, A; Humphreys, I; Harrison, G; et al. (2011)